Shanghai Jiaoda OnllyLtd Valuation

Is 600530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600530 (CN¥3.27) is trading above our estimate of fair value (CN¥0.05)

Significantly Below Fair Value: 600530 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600530?

Key metric: As 600530 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600530. This is calculated by dividing 600530's market cap by their current revenue.
What is 600530's PS Ratio?
PS Ratio	9x
Sales	CN¥282.61m
Market Cap	CN¥2.53b

600530 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.3x
Enterprise Value/EBITDA	111.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 600530's PS Ratio compare to its peers?

The above table shows the PS ratio for 600530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.6x
688793 Shenzhen Breo Technology	2.1x	19.9%	CN¥2.5b
301108 Tongling Jieya Biologic Technology	3.7x	23.7%	CN¥2.2b
603059 Perfect Group	1.8x	26.3%	CN¥2.2b
603102 Weihai Baihe Biology Technological	2.7x	n/a	CN¥2.3b
600530 Shanghai Jiaoda OnllyLtd	9x	n/a	CN¥2.5b

Price-To-Sales vs Peers: 600530 is expensive based on its Price-To-Sales Ratio (9x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does 600530's PS Ratio compare vs other companies in the CN Personal Products Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap

No more companies available in this PS range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 600530 is expensive based on its Price-To-Sales Ratio (9x) compared to the CN Personal Products industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is 600530's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600530 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600530's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Byhealth

CN¥20.9b

Develops and sells dietary supplements.

300146

CN¥12.40

-3.9%

-32.3%

Shenzhen Breo Technology

CN¥2.5b

Researches and develops portable massage products for headache swelling, eye fatigue, and shoulder and neck pain.

688793

CN¥29.69

-1.7%

-24.3%

SYoung Group

CN¥4.8b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.30

-4.1%

-27.0%